Mostrar el registro sencillo del ítem

dc.contributor.authorRodríguez, María R.
dc.contributor.authorBalsa, Lucía M.
dc.contributor.authorPlá, Julián del
dc.contributor.authorGarcía Tojal, Javier 
dc.contributor.authorPis Diez, Reinaldo
dc.contributor.authorParajón Costa, Beatriz S.
dc.contributor.authorLeón, Ignacio E.
dc.contributor.authorGonzález Baró, Ana C.
dc.date.accessioned2020-01-08T10:10:24Z
dc.date.available2020-01-08T10:10:24Z
dc.date.issued2019
dc.identifier.issn1144-0546
dc.identifier.urihttp://hdl.handle.net/10259/5200
dc.description.abstractFrom the interaction of the vanadyl ion with a ligand (HL), obtained by the condensation reaction of o-vanillin and 2-thiophenemethylamine, an oxidovanadium(IV) complex (VOL2) was obtained. It was characterized by spectroscopic techniques, including solid state FTIR, Raman, EPR and diffuse reflectance, and UV-vis and EPR, in solution. Its thermal behavior was analyzed by means of TGA and DTA. Theoretical studies based on DFT computational methods aided in the interpretation and assignment of spectroscopic data. Cytotoxicity assays (48 h) against bone cancer cells (MG-63, IC50 = 50.4 ± 8.7), breast cancer cells (MCF-7, IC50 = 42.3 ± 4.7), (MDA-MB-231, IC50 = 29.0 ± 1.7) and a normal fibroblast (L929, IC50 = 71.0 ± 3.5) demonstrated the enhancement of the effectiveness and selectivity of the complex as compared with both the ligand and the free metal ion. Besides, the compound inhibits cell migration, increases ROS levels and facilitates apoptosis. On a whole, these results show the main mechanisms of the deleterious effects of [VOL2] in a triple negative breast cancer cell line (MDA-MB-231), demonstrating that this complex is a promising therapeutic agent for this kind of breast cancer.en
dc.description.sponsorshipCONICET-CCT-La Plata (PIP 0651 and 0034), ANPCyT (PICT 2016-1574) and UNLP (11/X763) Argentina and also by Consejerı´a de Educacio´n CyL and FFEDER BU076U16, BU022G18 and Ministerio de Economı´a y Competitividad CTQ2016-75023-C2-1-P and CTQ2015-70371- REDT MetDrugs Network (Spain)es
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherRoyal Society of Chemistry
dc.relation.ispartofNew Journal of Chemistry. 2019, V. 43, n. 29, p. 11784-11794
dc.subject.otherQuímica inorgánicaes
dc.subject.otherChemistry, Inorganicen
dc.titleSynthesis, characterization, DFT calculations and anticancer activity of a new oxidovanadium(iv) complex with a ligand derived from o-vanillin and thiopheneen
dc.typeinfo:eu-repo/semantics/article
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.relation.publisherversionhttps://doi.org/10.1039/C9NJ02092F
dc.identifier.doi10.1039/C9NJ02092F
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCyL/BU076U16
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCyL/BU022G18
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/CTQ2016-75023-C2-1-P
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/CTQ2015-70371- REDT
dc.relation.projectIDinfo:eu-repo/grantAgreement/CONICET-CCT-La Plata/PIP-0651
dc.relation.projectIDinfo:eu-repo/grantAgreement/CONICET-CCT-La Plata/PIP-0034
dc.relation.projectIDinfo:eu-repo/grantAgreement/ANPCyT/PICT 2016-1574
dc.relation.projectIDinfo:eu-repo/grantAgreement/UNLP/11-X763
dc.identifier.essn1369-9261
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion


Ficheros en este ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem